229 related articles for article (PubMed ID: 27221971)
21. Lactic acidosis rates in type 2 diabetes.
Brown JB; Pedula K; Barzilay J; Herson MK; Latare P
Diabetes Care; 1998 Oct; 21(10):1659-63. PubMed ID: 9773726
[TBL] [Abstract][Full Text] [Related]
22. Adverse event notifications implicating metformin with lactic acidosis in Australia.
Huang W; Castelino RL; Peterson GM
J Diabetes Complications; 2015; 29(8):1261-5. PubMed ID: 26104729
[TBL] [Abstract][Full Text] [Related]
23. Lactic Acidosis in Diabetic Population: Is Metformin Implicated? Results of a Matched Case-Control Study Performed on the Type 2 Diabetes Population of Grenoble Hospital University.
Lepelley M; Giai J; Yahiaoui N; Chanoine S; Villier C
J Diabetes Res; 2016; 2016():3545914. PubMed ID: 27034959
[TBL] [Abstract][Full Text] [Related]
24. Lactic acidosis due to metformin in type 2 diabetes mellitus and chronic kidney disease stage 3-5: is it significant?
Prabhu RA; Mareddy AS; Nagaraju SP; Rangaswamy D; Guddattu V
Int Urol Nephrol; 2019 Jul; 51(7):1229-1230. PubMed ID: 30963454
[TBL] [Abstract][Full Text] [Related]
25. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Salpeter S; Greyber E; Pasternak G; Salpeter E
Cochrane Database Syst Rev; 2003; (2):CD002967. PubMed ID: 12804446
[TBL] [Abstract][Full Text] [Related]
26. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Salpeter S; Greyber E; Pasternak G; Salpeter E
Cochrane Database Syst Rev; 2002; (2):CD002967. PubMed ID: 12076461
[TBL] [Abstract][Full Text] [Related]
27. The safety and pharmacokinetics of metformin in patients with chronic liver disease.
Smith FC; Stocker SL; Danta M; Carland JE; Kumar SS; Liu Z; Greenfield JR; Braithwaite HE; Cheng TS; Graham GG; Williams KM; Day RO
Aliment Pharmacol Ther; 2020 Mar; 51(5):565-575. PubMed ID: 31960986
[TBL] [Abstract][Full Text] [Related]
28. Lactic acidosis induced by metformin in a chronic hemodialysis patient with diabetes mellitus type 2.
Altun E; Kaya B; Paydaş S; Sarıakçalı B; Karayaylalı I
Hemodial Int; 2014 Apr; 18(2):529-31. PubMed ID: 24299454
[TBL] [Abstract][Full Text] [Related]
29. [Chronic kidney diseases, metformin and lactic acidosis].
Borbély Z
Vnitr Lek; 2016 Apr; 62(4):299-303. PubMed ID: 27250607
[TBL] [Abstract][Full Text] [Related]
30. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Salpeter SR; Greyber E; Pasternak GA; Salpeter EE
Cochrane Database Syst Rev; 2010 Apr; 2010(4):CD002967. PubMed ID: 20393934
[TBL] [Abstract][Full Text] [Related]
31. Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements.
van Berlo-van de Laar IR; Vermeij CG; Doorenbos CJ
J Clin Pharm Ther; 2011 Jun; 36(3):376-82. PubMed ID: 21545617
[TBL] [Abstract][Full Text] [Related]
32. The cumulative dose-dependent effects of metformin on the development of tuberculosis in patients newly diagnosed with type 2 diabetes mellitus.
Heo E; Kim E; Jang EJ; Lee CH
BMC Pulm Med; 2021 Sep; 21(1):303. PubMed ID: 34563159
[TBL] [Abstract][Full Text] [Related]
33. Metformin therapy in patients with chronic kidney disease.
Duong JK; Roberts DM; Furlong TJ; Kumar SS; Greenfield JR; Kirkpatrick CM; Graham GG; Williams KM; Day RO
Diabetes Obes Metab; 2012 Oct; 14(10):963-5. PubMed ID: 22564555
[TBL] [Abstract][Full Text] [Related]
34. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Salpeter SR; Greyber E; Pasternak GA; Salpeter Posthumous EE
Cochrane Database Syst Rev; 2010 Jan; (1):CD002967. PubMed ID: 20091535
[TBL] [Abstract][Full Text] [Related]
35. Association between Metformin Use and Risk of Lactic Acidosis or Elevated Lactate Concentration in Type 2 Diabetes.
Lee EY; Hwang S; Lee YH; Lee SH; Lee YM; Kang HP; Han E; Lee W; Lee BW; Kang ES; Cha BS; Lee HC
Yonsei Med J; 2017 Mar; 58(2):312-318. PubMed ID: 28120561
[TBL] [Abstract][Full Text] [Related]
36. Use of metformin and risk of kidney cancer in patients with type 2 diabetes.
Tseng CH
Eur J Cancer; 2016 Jan; 52():19-25. PubMed ID: 26630530
[TBL] [Abstract][Full Text] [Related]
37. Effects of metformin use on total mortality in patients with type 2 diabetes and chronic obstructive pulmonary disease: A matched-subject design.
Yen FS; Chen W; Wei JC; Hsu CC; Hwu CM
PLoS One; 2018; 13(10):e0204859. PubMed ID: 30286138
[TBL] [Abstract][Full Text] [Related]
38. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.
Roumie CL; Hung AM; Greevy RA; Grijalva CG; Liu X; Murff HJ; Elasy TA; Griffin MR
Ann Intern Med; 2012 Nov; 157(9):601-10. PubMed ID: 23128859
[TBL] [Abstract][Full Text] [Related]
39. Metformin in chronic kidney disease: time for a rethink.
Heaf J
Perit Dial Int; 2014 Jun; 34(4):353-7. PubMed ID: 24711640
[TBL] [Abstract][Full Text] [Related]
40. Hypoglycemia Incidence Rates and Associated Health Care Costs in Patients with Type 2 Diabetes Mellitus Treated with Second-Line Linagliptin or Sulfonylurea After Metformin Monotherapy.
Raju A; Shetty S; Cai B; D'Souza AO
J Manag Care Spec Pharm; 2016 May; 22(5):483-92. PubMed ID: 27123911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
